New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures New data sought to evaluate the MiniMed™ 780G ...

DUBLIN, June 11, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Marking of its MiniMed™ 780G system, a next ...

A first-of-its-kind meta-analysis comparing multiple automated insulin delivery (AID) systems in people with type 1 diabetes has found that Medtronic's MiniMed 780G achieved the highest time in target ...

GALWAY, Ireland, Sept. 2, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory milestones ...

Mealtimes are one of the biggest challenges for people living with type 1 diabetes and frequently linked to diabetes distress.1,2 The constant need for decision-making and mental load around ...

DUBLIN, Jan. 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for the MiniMed™ 780G system with ...

Data from the LENNY trial, recently published in The Lancet Diabetes & Endocrinology, demonstrated the safety and efficacy i of the MiniMed™ 780G system in children aged 2-6 years old with type 1 ...

With its advanced algorithm that provides autocorrections every 5 minutes, the latest data demonstrated that the MiniMed™ 780G system decreased rates of early morning hyperglycemia, known as dawn ...

Medtronic plc MDT recently announced two regulatory milestones for its MiniMed 780G system portfolio. The FDA has cleared the company’s SmartGuard algorithm as an interoperable automated glycemic ...

"While labeling requires meal bolusing for all automated insulin delivery systems, including the MiniMed™ 780G system, missed boluses are a reality in real-world use," said Jennifer McVean, MD, Senior ...